The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials

Zhao, Tingting; Xu, Hao; Xu, Hui; Wang, Zhenning; Xu, Yingying; Song, Yongxi; Yin, Saifu; Liu, Xingyu; Zhang, Miao

doi:10.1007/s10120-018-0813-2

Cited by 56 publications

(62 citation statements)

References 35 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a network meta-analysis evaluated the efficacy and safety of targeted drugs (mainly including apatinib, regorafenib, rilotumumab, everolimus, bevacizumab, and sunitinib) with or without chemotherapy in advanced GC treatment and demonstrated that apatinib showed the best improvement in PFS, OS, and overall response rate. 43 …”

Section: The Clinical Research Regarding Apatinibmentioning

confidence: 99%

Progress in the treatment of solid tumors with apatinib: a systematic review

Zhao

Zhang

2018

OTT

View full text Add to dashboard Cite

With the investigation of molecular targets, many agents, such as trastuzumab and ramucirumab, have attained a positive outcome in oncotherapy. Vascular endothelial growth factor (VEGF) is considered a potent factor in angiogenesis and plays an important role in the growth of tumors. Moreover, both VEGF and its receptor are usually excessively expressed in solid tumors and could be hopeful targets for the treatment of neoplasms. Apatinib (YN968D1) is an oral small-molecule tyrosine kinase inhibitor of VEGFR-2. By inhibiting several signaling transduction pathways, it restrains angiogenesis and subsequently controls tumorigenesis. According to current studies, apatinib shows promising application in various solid tumors as a post-second- and post-third-line treatment. It could significantly improve the median overall survival and progression-free survival of patients with tolerated adverse reactions. This paper aims to summarize the recent research on apatinib including the mechanism, pharmacokinetics, trials, adverse reactions, and prospect as a treatment.

show abstract

Section: The Clinical Research Regarding Apatinibmentioning

confidence: 99%

Progress in the treatment of solid tumors with apatinib: a systematic review

Zhao

Zhang

2018

OTT

View full text Add to dashboard Cite

show abstract

“…Gastric cancer (GC) is a severe malignant tumour associated with high mortality, especially in Asia 1,2 . Due to the non-specific symptoms in early appearance and the poor prognosis, the 5-year relative survival rate for GC was at most 20% 3 .…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis and anticancer activity of naphthoquinone derivatives

Shen

Wang

Han

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Basis on molecular docking and pharmacophore analysis of naphthoquinone moiety, a total of 23 compounds were designed and synthesised. With the help of reverse targets searching, anti-cancer activity was preliminarily evaluated, most of them are effective against some tumour cells, especially compound 12: 1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl-4-oxo-4-((4-phenoxyphenyl)amino) butanoate whose IC 50 against SGC-7901 was 4.1 ± 2.6 lM. Meanwhile the anticancer mechanism of compound 12 had been investigated by AnnexinV/PI staining, immunofluorescence, Western blot assay and molecular docking. The results indicated that this compound might induce cell apoptosis and cell autophagy through regulating the PI3K signal pathway.

show abstract

“…Similar results were published for these cancer treatments approved by the U.S. Food and Drug Administration [ 7 ]. It has repeatedly been reported that survival benefit of targeted therapy may come at the cost of toxicity potentiation when provided alone [ 8 ] or in combination with standard or chemotherapy [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. A plethora of studies have been published documenting, besides good clinical outcome, potentiation of toxicities in combination treatment of chemotherapy or standard therapy with mAbs, targeted treatment, or immunotherapy [ 9 , 10 , 11 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

et al. 2018

View full text Add to dashboard Cite

Background: Despite improvement of tumor response rates, targeted therapy may induce toxicities in cancer patients. Recent studies indicate amelioration of adverse events (AEs) by add-on mistletoe (Viscum album L., VA) in standard oncological treatment. The primary objective of this multicenter observational study was to determine the safety profile of targeted and add-on VA therapy compared to targeted therapy alone. Methods: Demographic and medical data were retrieved from the Network Oncology registry. Allocation to either control (targeted therapy) or combinational group (targeted/add-on VA) was performed. Safety-associated variables were evaluated by adjusted multivariable analyses. Results: The median age of the study population (n = 310) at first diagnosis was 59 years; 67.4% were female. In total, 126 patients (40.6%) were in the control and 184 patients (59.4%) in the combination group. Significant differences were observed between both groups with respect to overall AE frequency (χ2 = 4.1, p = 0.04) and to discontinuation of standard oncological treatment (χ2 = 4.8, p = 0.03) with lower rates in the combinational group (20.1%, 35% respectively) compared to control (30.2%, 60.5%, respectively). Addition of VA to targeted therapy significantly reduced the probability of oncological treatment discontinuation by 70% (Odds ratio (OR) 0.30, p = 0.02). Conclusions: Our results indicate a highly significant reduction of AE-induced treatment discontinuation in all-stage cancer patients when treated with VA in addition to targeted therapy.

show abstract

The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials

Cited by 56 publications

References 35 publications

Progress in the treatment of solid tumors with apatinib: a systematic review

Progress in the treatment of solid tumors with apatinib: a systematic review

Design, synthesis and anticancer activity of naphthoquinone derivatives

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

Contact Info

Product

Resources

About